Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio sulla terapia cardiaca neurale per l'insufficienza cardiaca (NECTAR-HF) (NECTAR-HF)

26 ottobre 2026 aggiornato da: Boston Scientific Corporation

Terapia cardiaca neurale per studio sull'insufficienza cardiaca

The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The objectives of this study are to assess the impact of right vagal nerve stimulation on left ventricular remodeling, functional capacity, quality of life, and other measures in heart failure patients over a 6-month period. In addition, the study will assess the safety of the NECTAR-HF study system over an 18-month period.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

118

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Brussels, Belgio, 1200
        • UCL Bruxelles
      • Prague, Cechia, 15030
        • Nemocnice Na Homolce
      • Lille, Francia, 59037
        • CHRU de Lille - Hôpital Cardiologique
    • Nancy
      • Vandœuvre-lès-Nancy, Nancy, Francia, 54500
        • Centre d'Investigation Clinique Pierre Drouin, CHU de Nancy
      • Göttingen, Germania, 37075
        • Universitätsmedizin Göttingen
      • Hamburg, Germania, 20246
        • Universitäres Herzzentrum GmbH, Universitätsklinikum Hamburg-Eppendorf
      • Leipzig, Germania, 04103
        • Universitätsklinikum Leipzig
    • Brandenburg
      • Bernau bei Berlin, Brandenburg, Germania, 16321
        • Immanuel Klinikum Bernau Herzzentrum Brandenburg
      • Milan, Italia, 20162
        • Azienda Ospedaliera Niguarda Cà Granda
      • Naples, Italia, 80131
        • A. O. Dei Colli - Monaldi
      • Pavia, Italia, 27100
        • Policlinico San Matteo
      • Eindhoven, Olanda, 5623EJ
        • Catharina Ziekenhuis Eindhoven
      • Utrecht, Olanda, 3584CX
        • UMC Utrecht
      • London, Regno Unito, SE5 9RS
        • King's College Hospital NHS Foundation Trust
    • England
      • Bristol, England, Regno Unito, BS2 8HW
        • University Hospitals Bristol, NHS Foundation Trust
      • Liverpool, England, Regno Unito, L14 3PD
        • Liverpool Heart and Chest Hospital, NHS Foundation Trust
      • London, England, Regno Unito, W1G 8PH
        • The Heart Hospital, University College London Hospitals, NHS Foundation Trust
      • London, England, Regno Unito, W2 1NY
        • Imperial College Healthcare NHS Trust, St. Mary's Hospital
      • Barcelona, Spagna, 08036
        • Hospital Clinic de Barcelona
      • Madrid, Spagna, 28041
        • Hospital Doce de Octubre
    • Navarre
      • Pamplona, Navarre, Spagna, 31008
        • Clínica Universitaria de Navarra, Avenida Pio XII s/n

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 18 or above, and of legal age to give informed consent specific to national laws
  • Willing and capable of providing informed consent
  • Capable of participating in all testing associated with this clinical investigation
  • Stable symptomatic heart failure NYHA class II-III
  • Left ventricular (LV) ejection fraction equal or smaller than 35 %
  • Left ventricular end diastolic diameter (LVEDD) of 5.5 cm or greater
  • Prescribed to optimal pharmacologic therapy

Exclusion Criteria:

  • QRS larger than 130 ms
  • Patients who have been hospitalized for heart failure and who required the use of HF IV therapy within 30 days before enrollment
  • Patients unable to tolerate anesthesia required for implant
  • Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass graft, cerebral vascular accident, or transient ischemic attack within previous 90 days before enrollment
  • Patients whose primary cause of heart failure is mitral or aortic valve disease, with a severe classification
  • Patients with persistent or permanent atrial fibrillation within 90 days prior to enrollment
  • Pacemaker indicated patients
  • Patients whose heart failure is due to congenital heart disease
  • Patients who have started treatment for sleep apnea or sleep disordered breathing with therapies to maintain airway patency (e.g., CPAP, Bi-PAP,APAP) with or without oxygen supplementation within the previous 6 months prior to enrollment
  • Patients with hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis)
  • Patients with documented chronic obstructive lung disease
  • Patients on or indicated for renal dialysis
  • Type 1 diabetic patients
  • Type 2 diabetic patients that have been treated with insulin for more than 5 years prior to enrollment
  • Patients with a life expectancy of less than 12 months per physician judgment
  • Patients involved in any concurrent clinical investigation
  • Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding
  • Patients with a prior cardiac transplant or expecting a heart transplant operation within the next 12 months
  • Patients with a prior vagotomy
  • Patients with prior or existing vagal nerve stimulation treatment
  • Patients implanted with any active implantable medical device other than a left sided single or dual chamber implantable cardioverter defibrillator (ICD) with bipolar sensing, or a left sided CRT device with each sensing channel programmed to either bipolar sensing or no sensing. All CRT patients must have had CRT for at least 1 year prior to enrollment. The total number of CRT patients will not exceed 30
  • Patients with locally implanted semi-/permanent devices such as vascular catheters, etc. that would interfere with the NECTAR-HF study system
  • Patients with previously implanted devices on the right side that became infected before removal
  • Patients with previous neck surgery and resultant scar formation that interferes with the ability to implant the study system on the right side of the neck (Thyroid/parathyroid, carotid artery etc)
  • Patients with known recurrent nerve paralysis
  • Patients who have undergone radiotherapy for thyroid disease/cancer
  • Patients who have existing or prior tracheotomy
  • Patients with severe vertebral cervical disease and limited mobility in the neck; includes those that frequently wear a brace
  • Patients with carotid murmur/vascular bruit/carotid artery lesion
  • Patients with known/suspected vascular malformation in carotid/vertebral circulatory bed
  • Patients who are likely to need an MRI of the neck area because of previous medical conditions

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Therapy

Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.

The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.

Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.

Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.

Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.

Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Blood draw before implant and 6 months after implant at the end of the randomization phase.

Comparatore fittizio: Control

Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.

Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current.

Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Blood draw before implant and 6 months after implant at the end of the randomization phase.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Left Ventricular End-systolic Dimension (LVESD)
Lasso di tempo: LVESD at Baseline and at 6-months post Baseline

Change in the Left ventricular end-systolic dimension (LVESD) between Baseline and the value at the end of the randomization phase (6 months after Baseline) i.e. 6 months after vagus nerve stimulation in the THERAPY Arm. No Vagus nerve stimulation during that time window in the CONTROL Arm.

The sign (- ) indicates a reduction in the LVESD. Minus means a reduction in LVESD.

The change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 6 months minus value at baseline).

LVESD at Baseline and at 6-months post Baseline
Percentage of Surviving Participants
Lasso di tempo: 18-months

As pre-specified in the study protocol, the All-cause Survival endpoint combined both groups into one analysis population. Subjects contributed data according to the follow-up period during they received VNS therapy (Implant through 18 months for Therapy subjects, 6 through 18 months for Control subjects). Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded.

18-months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
LVEF, Left Ventricular Ejection Fraction
Lasso di tempo: LVEF at Baseline and at 6-months after Baseline

LVEF, left ventricular ejection fraction.

LVEF at Baseline and at 6-months after Baseline
Exercise Capacity, Peak VO2
Lasso di tempo: Measurements at Baseline and at 6-months after Baseline

Assessment of functional capacity (e.g., peak VO2) as measures related to patient heart failure status.

Measurements at Baseline and at 6-months after Baseline
LVESV, Left Ventricular End Systolic Volume
Lasso di tempo: At Baseline and at 6-months after Baseline

Measurements of LVESV, left ventricular end systolic volume at Baseline and 6 months after Baseline in the Control Arm and in the Therapy Arm

At Baseline and at 6-months after Baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Faiez Zannad, M.D., Centre d'Investigation Clinique (CIC), Batiment Louis Mathieu, CHU de Nancy

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

21 settembre 2011

Completamento primario (Effettivo)

1 maggio 2014

Completamento dello studio (Stimato)

30 giugno 2027

Date di iscrizione allo studio

Primo inviato

28 giugno 2011

Primo inviato che soddisfa i criteri di controllo qualità

28 giugno 2011

Primo Inserito (Stimato)

30 giugno 2011

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

26 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NECTAR-1109

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .